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http://www.biomedcentral.com/1471-230X/12/136RESEARCH ARTICLE Open AccessUse of health care services and pharmaceutical
agents in coeliac disease: a prospective
nationwide study
Anniina Ukkola1,2, Kalle Kurppa2, Pekka Collin1,3, Heini Huhtala4, Leena Forma4, Leila Kekkonen5, Markku Mäki2
and Katri Kaukinen1,3*Abstract
Background: Approximately 1% of the population suffer from coeliac disease. However, the disease is heavily
underdiagnosed. Unexplained symptoms may lead to incremented medical consultations and productivity losses.
The aim here was to estimate the possible concealed burden of untreated coeliac disease and the effects of a
gluten-free diet.
Methods: A nationwide cohort of 700 newly detected adult coeliac patients were prospectively evaluated. Health
care service use and sickness absence from work during the year before diagnosis were compared with those in
the general population; the data obtained from an earlier study. Additionally, the effect of one year on dietary
treatment on the aforementioned parameters and on consumption of pharmaceutical agents was assessed.
Results: Untreated coeliac patients used primary health care services more frequently than the general population.
On a gluten-free diet, visits to primary care decreased significantly from a mean 3.6 to 2.3. The consumption of
medicines for dyspepsia (from 3.7 to 2.4 pills/month) and painkillers (6.8-5.5 pills/month) and the number of
antibiotic courses (0.6-0.5 prescriptions/year) was reduced. There were no changes in hospitalizations, outpatient
visits to secondary and tertiary care, use of other medical services, or sickness absence, but the consumption of
nutritional supplements increased on treatment.
Conclusions: Coeliac disease was associated with excessive health care service use and consumption of drugs
before diagnosis. Dietary treatment resulted in a diminished burden to the health care system and lower use of
on-demand medicines and antibiotic treatment. The results support an augmented diagnostic approach to reduce
underdiagnosis of coeliac disease.
Trial registration: ClinicalTrials.gov NCT01145287
Keywords: Coeliac disease, Gluten-free diet, Burden of illness, Health care service use, Sickness absenceBackground
Untreated coeliac disease may cause a significant burden
to the health care system. The disease is one of the com-
monest chronic gastrointestinal disorders, with a preva-
lence of up to 2% in the adult population [1], the figure
in fact even increasing [2]. The clinical picture is* Correspondence: katri.kaukinen@uta.fi
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reproduction in any medium, provided the orheterogeneous and comprises mild or extraintestinal
symptoms such as osteoporosis and neurological com-
plaints [3,4]. Up to 90 per cent of coeliac disease patients
remain undiagnosed [1,5,6] and may suffer from
impaired health and repeatedly seek help for non-specific
complaints [7-9]. This may lead to excessive use of health
services, for example frequent outpatient visits and ex-
pensive medical investigations. Furthermore, physicians
or patients themselves may try to treat the unexplained
symptoms and poor well-being with a variety of pharma-
ceutical agents or micronutrients in addition to non-
medical treatments. Possible false diagnoses and futileLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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system. It could also be hypothesized that undetected
coeliac disease leads to an increased number of days of
absence from work. As treatment with a gluten-free diet
usually results in alleviation of symptoms it could thus
also diminish the burden related to the disease. Remark-
ably, the mean diagnostic delay in coeliac disease is be-
tween 4 and 13 years [8-12], indicating that the burden
caused by undiagnosed disease might be long-standing.
Now that accurate serological screening tests are avail-
able for screening for coeliac disease, an active screening
policy would shorten this period of latency and reduce
the burden related to undetected disease. The data thus
far available on the use of health care services, consump-
tion of symptom-targeted medication and sickness ab-
sence among undiagnosed and treated coeliac disease
patients are limited.
In this country, an increasing number of coeliac disease
patients are diagnosed in primary health care [13]. Due to
intensified case finding and screening, mild or atypical
symptoms dominate the clinical picture and the detection
rate is up to 0.7% . We aimed here to estimate prospect-
ively the possible concealed burden of untreated coeliac
disease and the effects of a gluten-free diet in a large na-
tionwide cohort of newly detected coeliac disease patients.
We also compared the results of health care service use
and reported days of absence from work with national
data from the general Finnish population during the same
period.
Methods
A nationwide cohort of consecutive newly detected
coeliac disease patients were prospectively evaluated. A
structured and validated study questionnaire was mailed
to all new members joining the Finnish Coeliac Society
between February 2007 and May 2008. In Finland, ap-
proximately 70% of coeliac disease patients join the So-
ciety shortly after being diagnosed. Respondents over
16 years of age with biopsy-proven coeliac disease diag-
nosed within one year were eligible. A follow-up ques-
tionnaire was sent to all respondents after one year.
The questionnaires were designed in co-operation with
the Finnish Coeliac Society, coeliac disease patients and
clinical researchers with expertise in the disease [14],
and comprised questions on personal health, clinical
presentation and issues related to the diagnosis. Self-
reported consumption of on-demand pharmaceutical
agents and supplements, both prescribed and over-the-
counter agents, was inquired. Patients were asked to re-
port separately for each type of pharmaceutical agent
the number of pills per month consumed on average
during the years prior to and following the diagnosis.
The use of antibiotics was reported as the number of
courses during the study periods. The use of healthcare services, including all-cause visits (inpatient, out-
patient, other medical services; the causes of visits were
not asked) and also visits related to the diagnosis and
follow-up were recorded during one year prior to the
diagnosis of coeliac disease and after initiation of a
gluten-free diet (patients were asked to fill in the num-
ber of each kind of visits). Patients were also asked to
report the number of days of sickness absence from
work during the same periods. The appropriateness of
the questions together with the face and content valid-
ity of the tested items were pre-tested by a group of
coeliac disease members of the Society as previously
described [14]. Test-retest reliability was established
using an intraclass correlation coefficient. For the key
items measured, the kappa values for test-retest reliabil-
ity ranged from 0.84 to 1.00 (values above 0.70 being
regarded as excellent). For the use of health care ser-
vices, the kappa values ranged from 0.94 to 1.00, for
the consumption of pharmaceutical agents from 0.90 to
1.00 and for the number of days of sickness absence
0.99. All data were blindly coded before analyses. The
study protocol was approved by the review board of the
Finnish Coeliac Society in compliance with all applicable
Finnish laws for registered organizations and governing
the protection of human subjects. Informed consent was
obtained from all study subjects after a full written explan-
ation of the aims of the study, including considerations
regarding ethics and data protection and the anonymous
deposition of the questionnaires.
Data on self-reported visits to a physician and days of
absence from work among the general Finnish popula-
tion during the same period (2007–2008) were obtained
from an annual nationwide postal survey conducted by
the National Institute for Health and Welfare since
1978. The surveys are mailed to a random sample of
5000 Finnish adults (15–64 years of age) each year
[15,16]. Characteristics of the population controls are
shown in Additional file 1. In that study, the partici-
pants were asked to report the total number of all-
cause medical consultation with a physician including
hospitalizations. The number of days of sickness ab-
sence was asked similarly as here. In the present study,
comparisons on the aforementioned issues between the
coeliac group and the general population were limited
to study subjects of the same age. The groups were not
adjusted for gender.
Statistical analyses were performed using SPSS version
17.0 (SPSS Inc., Chicago, IL, USA). All testing was two-
sided and p < 0.05 was considered statistically significant.
Chi square test and Fisher’s Exact test were used in cross
tabulations, Wilcoxon signed rank test for evaluating
changes within groups and Mann–Whitney U test for
assessing changes between groups. Results are given as
means and 95% confidence intervals (CI).
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The study questionnaires were mailed to 1864 coeliac
disease patients, of whom 1062 responded giving a re-
sponse rate of 57% . There were no differences in age or
gender distribution between respondents and non-
responders. Altogether 362 individuals were excluded: in
157 cases the diagnosis had been made more than one
year previously, 132 were under 16 years of age and 73
did not have a biopsy-proven diagnosis. Thus, 700 adult
patients were enrolled (Table 1). Of these, 679 (97% ) also
completed the follow-up survey. After one year, 86% of
the patients reported adherence to a strict gluten-free
diet, only two having continued on a gluten-containing
diet.
In the year prior to the diagnosis of coeliac disease,
85% of the patients had consulted a physician in primary
health care, 30% in secondary or tertiary health care,
12% had had at lest one admission to a hospital and 60%
had used other medical services (consultations with a
nurse, a psychologist or a dietician, home nursing care,
physiotherapy, laboratory and imaging services). After
one year on a gluten-free diet the corresponding propor-
tions were 74% , 26% , 13% and 65% , respectively. In
the year prior to the diagnosis, the patients had con-
sulted either a primary care or a hospital physician aTable 1 Baseline characteristics of the coeliac disease
study group
All Female Male
n = 700 n= 534
(76% )
n = 166
(24% )
Median age (range), years 49 (16–84) 48 (16–84) 53 (16–83)
Clinical presentation, %
Gastrointestinal symptoms
and signs
70 70 70
Extraintestinal symptoms 9 8 12
Detected by screening* 21 22 18
Duration of symptoms
Median (range), years 3 (0–59) 3 (0–51) 2 (0–59)
25-75th percentile 1-7 1-7 1-5
OEGD at diagnosis, % 100 100 100
OEGD prior to diagnosis
of CD, % *
21 19 27
Diagnosis was established in, %
Primary health care 52 55 42
Secondary health care 38 36 44
Tertiary health care 10 9 14
OEGD oesphago-gastroduodenoscopy.
CD coeliac disease.
* Screening performed because of patients belonged to a risk group
(first-degree relatives of coeliac disease patients, those with type 1 diabetes
mellitus, autoimmune thyroid disease, Sjögren’s syndrome and IgA deficiency).
† Other than the oesphago-gastroduodenoscopy by which the diagnosis of
coeliac disease was confirmed.mean 4.4 times. Of the respondents, 12% claimed they
had not consulted a physician. In the year following the
diagnosis while on a gluten-free diet, the corresponding
figure was 3.1 and no consultations with a physician was
reported by 18% . A significant reduction was observed
in use of primary health care services. There were no
changes in the number of consultations in secondary or
tertiary health care or in admissions to or consumption
of other medical services (Table 2). The use of health
care services assessed as all-cause consultations with a
physician and admissions to a hospital was significantly
higher in both genders in the coeliac disease group than
in the general population (p < 0.001) (Figure 1). After
one year on a gluten-free diet, no such difference was
observed. When analysed by age, all age groups (25 to
34, 35 to 44, 45 to 44 and 55 to 64 years old) except the
youngest age group (16 to 24 years old) had significantly
more consultations than the population controls at base-
line, p = 0.07, p < 0.001, p = 0,41 and p = 0.19, respect-
ively. After the follow-up, no differences were noted.
The reported number of days of sickness absence from
work was significantly lower in the coeliac group than in
the general population in the year prior to the diagnosis
(Figure 2A). Of those at working age and who were not
retired (n = 480), 50% stated they had no sickness ab-
sence compared to 35% in the general population. After
one year, the corresponding figures were 42% and 35% ,
respectively. In the year following the diagnosis, sickness
absences had increased to population level among males
but not among females (Figure 2B). When the male
group was analysed by age, only the youngest (16 to
24 years old) and the oldest (55 to 64 years old) age
groups differed significantly from the controls, p = 0.018
and p = 0.005, respectively. Those 55 to 64 years old had
the biggest increase in the number of days of absence, a
mean of 5.6 days. Among the youngest age group the
mean increase was 1.8 days.
The coeliac disease patients’ consumption of pharma-
ceutical agents in the year prior to and following the
diagnosis is shown in Table 3. There was a significant re-
duction in all on-demand medicines on treatment. In
particular, the use of drugs for dyspepsia decreased sig-
nificantly in both genders, and that of painkillers and the
number of antibiotic prescriptions in females (Table 3).
Of the patients, 74% reported having used on-demand
medication in the year before the diagnosis and 73% in
the year following the diagnosis. For painkillers the per-
centages of users were 65% and 66% and for medicines
for dyspepsia 26% and 18% , respectively. Of the
patients, 30% had peen prescribed antibiotics prior to
and 26% after the diagnosis.
In contrast to other pharmaceutical agents, the con-
sumption of vitamins, micronutrients and herbal pro-
ducts increased significantly in both genders on a
Table 2 Changes in the mean number of all-cause medical consultations among coeliac disease patients between the
year prior to and after the diagnosis of the disease
All Female Male
n = 700 n= 534 n= 166
Outpatient visits in primary health care
Year prior to diagnosis 3.6 3.7 3.1
Year after diagnosis on a GFD 2.3 2.5 1.9
Mean change (95% CI) −1.2 (−1.5 to −0.9) −1.3 (−1.6 to −0.9) −1.2 (−1.7 to −0.7)
P value <0.001 <0.001 <0.001
Outpatient visits in secondary and tertiary health care
Year prior to diagnosis 0.8 0.8 0.8
Year after diagnosis on a GFD 0.8 0.8 0.9
Mean change (95% CI) 0.0 (−0.2 to 0.1) 0.0 (−0.2 to 0.2) 0.0 (−0.3 to 0.4)
P value 0.664 0.630 0.906
Admissions to hospital
Year prior to diagnosis 0.2 0.2 0.2
Year after diagnosis on a GFD 0.2 0.2 0.2
Mean change (95% CI) 0.0 (−0.03 to 0.1) 0.0 (−0.1 to 0.1) 0.0 (−0.1 to 0.1)
P value 0.708 0.521 0.724
Other medical services*
Year prior to diagnosis 4.1 4.5 2.7
Year after diagnosis on a GFD 3.6 4.0 2.4
Mean change (95% CI) −0.5 (−1.0 to 0.1) −0.5 (−1.2 to 0.2) −0.3 (−1.2 to 0.7)
P value 0.340 0.245 0.797
GFD gluten-free diet.
CI confidence interval.
* Consultations with a nurse, a psychologist or a dietician, home nursing care, physiotherapy, laboratory and imaging services.
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sumption even more than female. While at diagnosis
49% of the patients reported at least occasional use of
vitamins, micronutrients or herbal products, the corre-
sponding figure after one year on treatment was 55%.
Discussion
In this prospective, nationally representative study we
found that untreated adults with coeliac disease made
more outpatient health care visits than the generalpopulation. In addition, implementation of a gluten-free
diet resulted in the disappearance of this increased con-
sumption of medical services. The burden of unrecognized
coeliac disease was concentrated particularly in primary
health care. In parallel to these findings, a significant re-
duction in the use of on-demand drugs and the number of
antibiotic prescriptions was observed while on dietary
treatment. To our knowledge, this was the first study to in-
vestigate sickness absence and consumption of on-demand
medication among coeliac disease patients.
Table 3 Changes in reported consumption of pharmaceutical agents among coeliac disease patients (pills per month
on average) between the year prior to and following the diagnosis of coeliac disease
All Female Male
n = 700 n= 534 n= 166
All on-demand medicines*
Year prior to diagnosis 12.0 12.2 11.4
Year after diagnosis on a GFD 9.3 9.1 10.0
Mean change (95% CI) −2.7 (−4.3 to −1.2) −3.1 (−4.9 to −1.4) −1.4 (−4.8 to 2.0)
P value <0.001 <0.001 0.011
Painkillers
Year prior to diagnosis 6.8 7.2 5.6
Year after diagnosis on a GFD 5.5 5.2 6.4
Mean change (95% CI) −1.3 (−2.6 to −0.1) −2.0 (−3.4 to −0.5) 0.8 (−2.1 to 3.7)
P value <0.001 <0.001 0.432
Medicines for dyspepsia
Year prior to diagnosis 3.7 3.5 4.4
Year after diagnosis on a GFD 2.5 2.4 2.6
Mean change (95% CI) −1.27 (−2.10 to −0.44) −1.1 (−2.0 to −1.2) −1.8 (−3.7 to 0.1)
P value <0.001 <0.001 0.015
Antibiotic treatment†
Year prior to diagnosis 0.6 0.7 0.4
Year after diagnosis on a GFD 0.5 0.5 0.3
Mean change (95% CI) −0.1 (−0.2 to −0.1) −0.2 (−0.3 to −0.1) −0.1 (−0.3 to 0.1)
P value 0.001 0.001 0.302
Vitamins, micronutrients, herbal products
Year prior to diagnosis 18.4 20.7 10.8
Year after diagnosis on a GFD 22.6 24.6 16.2
Mean change (95% CI) 4.2 (1.8 to 6.7) 3.9 (0.9 to 6.8) 5.5 (1.8 to 9.1)
P value <0.001 0.003 0.002
CI confidence interval.
GFD gluten-free diet.
* Painkillers, medicines for dyspepsia, sleeping pills.
† Not reported as pills per month but as number of courses per year.
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care services and symptom-targeted medication prior to
diagnosis might be related to the presence of diverse
symptoms: untreated coeliac disease is known to be
associated with various unspecific complaints – e.g. indi-
gestion and heart burn [17], regurgitation [18], migraine
[19] and joint pain [20], which may resolve on a gluten-
free diet. It has also been suggested that active coeliac
disease may be associated with an increased susceptibil-
ity to infections [21,22]. Our findings suggest that the
diagnosis and subsequent treatment of coeliac disease
are able to reduce the burden of disease in the health
care system in addition to the alleviated burden experi-
enced by patients [14].
Earlier data on the use of health care services in
coeliac disease are limited. Two recent retrospective
studies from the USA found that treatment with agluten-free diet resulted in decreased medical costs due
to reduced use of health care services among coeliac dis-
ease patients. However, these studies concentrated on
direct costs and obtained study participants in high-
volume referral centres or administrative claim registers
[23,24], which may limit extrapolation of the data to the
whole coeliac disease population. It is of note that the
main findings - excessive health care service use before
the diagnosis of coeliac disease and reduction in the
consumption of these services during a gluten-free diet -
were in line, despite the difference in settings between
these earlier trials and our current prospective nation-
wide study. However, in contrast to the results reported
by Long and associates [24] we found no difference in
the number of hospitalizations between the years prior
to and following the diagnosis of coeliac disease. In
addition, in the present study expenditure on laboratory
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sis. Even though direct medical costs were not evaluated
in the present study, the results of decreased use of
health care services and pharmaceutical agents suggest
decrease in costs for the health care system. In addition
to the studies mentioned earlier, another recent study
showed excess costs of undiagnosed symptomatic coeliac
disease patients and highlighted a largely advantageous
cost-benefit ratio for a diagnosis of the disease [25].
From an ethical point of view, as the aforementioned
studies have shown increased numbers of medical inves-
tigations before the diagnosis, it should be noticed how
many unnecessary invasive procedures (such as bone bi-
opsy and blood transfusions for unexplained anaemia,
colonoscopy for abdominal pain, computed tomography
for suspected inexistent neoplasms) could have been
saved in these patients if the disease would have been
diagnosed earlier.
Nowadays the proportion of coeliac disease patients
suffering from severe gastrointestinal symptoms and
malabsorption is decreasing and milder symptoms pre-
dominate. Consultations on these possibly vague and un-
specific symptoms might add to the burden in primary
health care, which patients first contact upon any com-
plaints. Additionally, the diagnostics and follow-up of
coeliac disease among adults are focused in primary
health care in Finland [13], all these aspects possibly
explaining the increased use of primary health care ser-
vices observed in the present study.
Even though the consumption of health care services
among coeliac disease patients was reduced to the popu-
lation level during one year on a gluten-free diet, further
studies are needed to establish the long-term impact of
dietary treatment. A recent study from Sweden reported
that, in spite of a median of 4 years on a gluten-free diet,
female coeliac disease patients used more health care
services than non-coeliac controls [26]. It was also
shown that the majority of complaints were related to
gastrointestinal symptoms, mental and behavioural dis-
orders and diseases of the musculoskeletal system. There
is further evidence that regardless of a long-term gluten-
free diet and histological remission, coeliac disease
patients may evince significant symptoms and impaired
health-related quality of life [27,28]. A recent study
found that impaired quality of life in coeliac disease
patients on a gluten-free diet is largely explained by co-
existence of irritable bowel syndrome and reflux [29].
It was somewhat surprising that the patients in our
study reported no increased sickness absence from work
prior to diagnosis. Actually, the number of days of absence
was even lower than that among the general population.
This would imply that currently the majority of coeliac
disease patients present with relatively mild clinical symp-
toms. However, although untreated coeliac disease isknown to be associated with increased anxiety and depres-
sion [30], reduced vitality [31] and sleeping disorders [32],
we did not here inquire in to the possible decrease in
productivity among undetected coeliac disease patients.
The reason why male but not female coeliac disease
patients increased their number of days of absence from
work in the follow-up remains unsolved. Possibly, once
given a diagnosis of a chronic disease the patients may
have thought to be “validated” or “vindicated” in being off
work. Unfortunately, we could not ascertain whether sick
leaves were concentrated during the period short after
diagnosis or were evenly distributed along the follow-up
period.
Even though decrease in the number of antibiotic pre-
scriptions was not big it can be regarded as clinically sig-
nificant. Two recent studies [33,34] have investigated
use of antibiotics and risk of developing Crohn’s disease
or ulcerative colitis. They found that subjects with those
diseases were more likely to have been prescribed anti-
biotics before the diagnosis. Shaw and associates [33]
speculated that the use of antibiotics could be a predis-
posing factor, whereas Virta and associates [34] consid-
ered that frequent use of antibiotics may trigger the
development of Crohn’s disease or be a sign of being
prone to infections before the intestinal disease is diag-
nosed. Our hypothesis about coeliac disease patients is
similar to the latter consideration and is supported by
the fact that fewer patients had been prescribed antibio-
tics post than pre-diagnosis. However, whether increased
use of antibiotics really is a predisposing factor to coeliac
disease or sign of decreased immunity because of un-
detected coeliac disease is out of the scope of this study
and needs further evaluations.
Interestingly, the use of vitamins, micronutrients and
herbal products increased significantly after the diagnosis
of coeliac disease. It has been reported that about 15-38%
of untreated coeliac disease patients suffer from anaemia
or nutritional deficiencies [35-37]. Nevertheless, these are
usually abolished on a gluten-free diet [35,38], and imple-
mentation of specific dietary supplements after the diag-
nosis is not routinely recommended in current clinical
guidelines [39]. Consequently, we believe that in most
cases the supplements were not prescribed by a physician
but started voluntarily by the patients. This is somewhat
worrying as increased use of vitamin and micronutrient
supplements in suggested to be related to increased risk
for cancer [40]. However, there have been alarming
results of dietary shortcomings among those following a
gluten-free diet as patients have been reported to con-
sume insufficient amounts of vitamins and micronutri-
ents [41,42]. This might be due to poor nutritional value
of commercial gluten-free products or inadequate dietary
choices. Thus, on the other hand, dietary supplements
may be needed.
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sidered a limitation to the study in that it may involve
inaccuracies. However, a unique strength of such a set-
ting in a nation-wide study was that by using self-
reported data it was possible to explore all aspects of
health care use instead of data captured in a single data-
base. Subsequently, we were able to assess not only
issues related to direct costs of care but also the indirect
burden falling on coeliac disease patients themselves.
However, similar methods have previously been used in
studies concerning gastrointestinal disorders and a recall
period covering the preceding twelve months in self-
reported use of health care services and pharmaceutical
agents has been shown to be feasible and reliable [43].
Moreover, patients were asked to report issues similarly
at baseline and in the follow-up, which makes the
changes observed more reliable and test-re-test reliabil-
ity for the key items was excellent. Likewise, the data on
the general population were based on self-reported
values asked similarly as in the present study. However,
the study questionnaires for the cohorts were different
which might have impacted the results. The response
rate in this study was relatively low but comparable to
those of earlier studies with similar study design [8,44].
A weakness of the study is that because we were unable
to ask about co-morbidities it was impossible to assess
their possible impact to the results.
Conclusions
Excessive use of primary health care services and
pharmaceutical agents was observed among untreated
coeliac disease patients. Treatment with a gluten-free
diet resulted in decreased consumption of health care
services, on-demand medicines and antibiotic prescrip-
tions. The results imply that unrecognized coeliac dis-
ease contributes markedly to the burden on affected
individuals and the health care system.
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